As a novel potassium-competitive acid blocker, VONOZOPRAN FUMARATE may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection.
Products still subject to third-party patent protection might be available solely for R&D purposes.
